<table id="t5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5  Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of Nevirapine (All interaction trials were conducted in HIV-1 positive subjects)  	
											</caption>
<colgroup>
<col valign="top" width="10%"></col>
<col valign="top" width="15%"></col>
<col valign="top" width="25%"></col>
<col align="center" width="5%"></col>
<col valign="top" width="15%"></col>
<col valign="top" width="15%"></col>
<col valign="top" width="15%"></col>
</colgroup>
<tfoot>
<tr>
<th align="left" colspan="4">§ = C<sub>min</sub> below detectable level of the assay
													</th>
</tr>
<tr>
<th align="left" colspan="4">↑ = Increase, ↓ = Decrease, ⇔ = No Effect
													</th>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" stylecode="Toprule Botrule Lrule Rrule" valign="middle">
<content stylecode="bold">Co-administered Drug</content>
</td>
<td align="left" stylecode="Toprule Botrule  Lrule  Rrule" valign="middle">
<content stylecode="bold">Dose of Co-administered Drug</content>
</td>
<td align="left" stylecode="Toprule Botrule LRule Rrule" valign="top">
<content stylecode="bold">Dose Regimen of Nevirapine</content>
</td>
<td align="center" stylecode="Toprule Botrule  Lrule  Rrule" valign="middle">
<content stylecode="bold">n</content>
</td>
<td align="left" colspan="3" stylecode="Toprule Botrule  Lrule  Rrule" valign="middle">
<content stylecode="bold">% Change of Co-administered Drug Pharmacokinetic Parameters (90% CI)</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals</content>
</td>
<td align="left" stylecode="Botrule  Lrule Rrule" valign="top"></td>
<td align="left" colspan="2" stylecode="Botrule  Lrule  Rrule" valign="top"></td>
<td align="left" stylecode="Botrule  Lrule  Rrule" valign="top">
<content stylecode="bold">AUC</content>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="bold">C</content>
<content stylecode="bold">
<sub>max</sub>
</content>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="bold">C</content>
<content stylecode="bold">
<sub>min</sub>
</content>
</td>
</tr>
<tr>
<td align="left" rowspan="2" stylecode="Botrule Lrule Rrule" valign="top">Atazanavir/Ritonavir<footnote id="FN13">For information regarding clinical recommendations, see <content stylecode="italics"> Drug Interactions (<linkhtml href="#s7">7</linkhtml>)</content>. </footnote>
<footnote id="FN16"> Parallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in    atazanavir PK are relative to atazanavir/ritonavir 300/100 mg alone.</footnote>
</td>
<td align="left" rowspan="2" stylecode="Toprule Botrule LRule Rrule" valign="top">300/100 mg QD day 4–13, then 400/100 mg QD, day 14–23</td>
<td align="left" rowspan="2" stylecode="Toprule Botrule LRule Rrule" valign="top">200 mg BID day 1-23. Subjects were treated with nevirapine prior to trial entry.</td>
<td align="center" rowspan="2" stylecode="Toprule Botrule LRule Rrule" valign="top">23</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>300/100 mg</content>
<br/>
<br/>														 ↓42<br/>														 (↓52 to ↓29)<br/>
<br/>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>
														300/100 mg <br/>
</content>
<br/>														↓28<br/>														(↓40 to ↓14)<br/>
<br/>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/> 300/100 mg <br/>
</content>
<br/> ↓72<br/> (↓80 to ↓60)<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/> 400/100 mg<br/>
</content>
<br/> ↓19<br/> (↓35 to ↑2)<br/>
<br/>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/> 400/100 mg<br/>
</content>
<br/> ↑2<br/> (↓15 to ↑24)<br/>
<br/>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/> 400/100 mg<br/>
</content>
<br/> ↓59 <br/> (↓73 to ↓40)<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Darunavir/Ritonavir <footnote id="FN17"> Based on between-trial comparison.</footnote>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">400/100 mg BID</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">200 mg BID</td>
<td align="center" stylecode="Botrule Lrule Rrule" valign="top">8</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">↑24 <br/> (↓3 to ↑57)<br/>
<br/>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">↑40 <br/> (↑14 to ↑73)<br/>
<br/>
</td>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">↑2 <br/> (↓21 to ↑32)<br/>
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Didanosine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">100-150 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">18</td>
<td align="center" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Efavirenz<footnoteref idref="FN13"></footnoteref>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">600 mg QD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 400 mg QD x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">17</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓28 <br/> (↓34 to ↓14)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓12 <br/>(↓23 to ↑1)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓32<br/>(↓35 to ↓19)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Fosamprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">1400 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg BID.  Subjects were treated with nevirapine prior to trial entry.</td>
<td align="left" stylecode="Botrule Rrule" valign="top">17</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓33 <br/>(↓45 to ↓20)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓25 <br/> (↓37 to ↑10)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓35 <br/> (↓50 to ↓15)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Fosamprenavir/Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">700/100 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg BID.  Subjects were treated with nevirapine prior to trial entry.</td>
<td align="left" stylecode="Botrule Rrule" valign="top">17</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓11<br/> (↓23 to ↓3)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓19 <br/> (↓32 to ↓4)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Indinavir<footnoteref idref="FN13"></footnoteref>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">800 mg q8H</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">19</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓31 (↓39 to ↓22)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓15 (↓24 to ↓4)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓44 (↓53 to ↓33)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Lopinavir<footnoteref idref="FN13"></footnoteref>
<footnote id="FN14"> Pediatric subjects ranging in age from 6 months to 12 years</footnote>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">300/75 mg/m2 (lopinavir/ ritonavir) <footnoteref idref="FN14"></footnoteref>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">7 mg/kg or 4 mg/ kg QD x 2 weeks; BID x 1 week</td>
<td align="left" stylecode="Botrule Rrule" valign="top">12, 15<footnote id="FN15">Parallel group design; n for Nevirapine  + lopinavir/ritonavir, n for lopinavir/ritonavir alone.</footnote>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓22 (↓44 to ↑9)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓14 (↓36 to ↑16)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓55 (↓75 to ↓19)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Lopinavir<footnoteref idref="FN13"></footnoteref>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">400/100 mg BID (lopinavir/ ritonavir)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID &gt; 1 year</td>
<td align="left" stylecode="Botrule Rrule" valign="top">22, 19<footnoteref idref="FN15"></footnoteref>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓27 (↓47 to ↓2)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓19 (↓38 to ↑5)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓51 (↓72 to ↓26)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Maraviroc<footnote id="FN18"> Based on historical controls</footnote>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">300 mg SD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">8</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑1 <br/> (↓35 to ↑55)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑54 <br/> (↓6 to ↑151)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">⇔</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule" valign="top">Nelfinavir<footnoteref idref="FN13"></footnoteref>
</td>
<td align="left" stylecode="Rrule" valign="top">750 mg TID</td>
<td align="left" stylecode="Rrule" valign="middle">200 mg QD x 14 days; <br/>200 mg BID x 14 days</td>
<td align="left" stylecode="Rrule" valign="top">23</td>
<td align="left" stylecode="Rrule" valign="top">⇔</td>
<td align="left" stylecode="Rrule" valign="top">⇔</td>
<td align="left" stylecode="Rrule" valign="top">↓32<br/> (↓50 to ↑5)</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule" valign="top">Nelfinavir-M8 metabolite</td>
<td align="left" stylecode="Rrule" valign="top"></td>
<td align="left" stylecode="Rrule" valign="top"></td>
<td align="left" stylecode="Rrule" valign="top"></td>
<td align="left" stylecode="Rrule" valign="top">↓62<br/> (↓70 to ↓53)</td>
<td align="left" stylecode="Rrule" valign="top">↓59<br/> (↓68 to ↓48)</td>
<td align="left" stylecode="Rrule" valign="top">↓66<br/> (↓74 to ↓55)</td>
</tr>
<tr>
<td align="left" stylecode="Toprule Botrule Lrule Rrule" valign="top">Ritonavir</td>
<td align="left" stylecode="Toprule Botrule Rrule" valign="top">600 mg BID</td>
<td align="left" stylecode="Toprule Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Toprule Botrule Rrule" valign="top">18</td>
<td align="left" stylecode="Toprule Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Toprule Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Toprule Botrule Rrule" valign="top">⇔</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Stavudine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">30-40 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">22</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Zalcitabine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">0.125-0.25 mg TID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">6</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Zidovudine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">100-200 mg TID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">11</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓28 (↓40 to ↓4)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓30 (↓51 to ↑14)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Other Medications</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" colspan="2" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">AUC</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">C</content>
<content stylecode="bold">max</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">C</content>
<content stylecode="bold">min</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule" valign="top">Clarithromycin<footnoteref idref="FN13"></footnoteref>
</td>
<td align="left" stylecode="Rrule" valign="bottom">500 mg BID</td>
<td align="left" stylecode="Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">15</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓31 (↓38 to ↓24)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓23 (↓31 to ↓14)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓56 (↓70 to ↓36)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Metabolite 14-OHclarithromycin</td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑42 (↑16 to ↑73)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑47 (↑21 to ↑80)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule" valign="bottom">Ethinyl estradiol<footnoteref idref="FN13"></footnoteref> and Norethindrone<footnoteref idref="FN13"></footnoteref>
</td>
<td align="left" stylecode="Rrule" valign="top">0.035 mg (as Ortho-Novum® 1/35)</td>
<td align="left" stylecode="Rrule" valign="bottom">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">10</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓20 (↓33 to ↓3)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">1 mg (as Ortho-Novum<sup>®</sup> 1/35)</td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓19 (↓30 to ↓7)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓16 (↓27 to ↓3)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Depomedroxyprogesterone acetate</td>
<td align="left" stylecode="Botrule Rrule" valign="top">150 mg every 3 months</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">32</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Fluconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">19</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Ketoconazole<footnoteref idref="FN13"></footnoteref>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">400 mg QD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">21</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓72 (↓80 to ↓60)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓44 (↓58 to ↓27)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Methadone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Individual Patient Dosing</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID ≥ 7 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">9</td>
<td align="left" colspan="3" stylecode="Botrule Rrule" valign="top">In a controlled pharmacokinetic trial with 9 subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 subjects. Methadone did not have any effect on nevirapine clearance.</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td stylecode="Toprule Rrule Lrule">Rifabutin<footnoteref idref="FN13"></footnoteref>
</td>
<td stylecode="Toprule Rrule">150 or 300 mg QD</td>
<td stylecode="Toprule Rrule">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td stylecode="Toprule Rrule">19</td>
<td stylecode="Toprule Rrule">↑17<br/> (↓2 to ↑40)</td>
<td stylecode="Toprule Rrule">↑28<br/> (↑9 to ↑51)</td>
<td stylecode="Toprule Rrule">⇔</td>
</tr>
<tr>
<td stylecode="Botrule Rrule Lrule">Metabolite<br/> 25-O-desacetyl-rifabutin</td>
<td stylecode="Botrule Rrule"></td>
<td stylecode="Botrule Rrule"></td>
<td stylecode="Botrule Rrule"></td>
<td stylecode="Botrule Toprule Rrule">↑24<br/>(↓16 to ↑84)</td>
<td stylecode="Botrule Toprule Rrule">↑29<br/> (↓2 to ↑68)</td>
<td stylecode="Botrule Toprule Rrule">↑22<br/> (↓14 to ↑74)</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Rifampin<footnoteref idref="FN18"></footnoteref>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">600 mg QD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days; 200 mg BID x 14 days</td>
<td align="left" stylecode="Botrule Rrule" valign="top">14</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑11 (↓4 to ↑28)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">⇔</td>
<td align="left" stylecode="Botrule Rrule" valign="top">§</td>
</tr>
</tbody>
</table>